Pharmaceutical giant Alkermes has announced that it plans to sell its Athlone facility to Danish healthcare company Novo Nordisk. The proposed sale of the development and manufacturing site, which is expected to cost around €84 million, is expected to be completed by the middle of next year. Alkermes CEO Richard Pops confirmed the company had entered into a definitive agreement for the sale of the company's Athlone site yesterday. He said it would offer current employees an exciting opportunity for growth.
Thilde Hummel Bogebjerg, a Senior Vice President with Novo Nordisk, said the company was excited that it would soon be welcoming 400 highly-skilled colleagues. The Senior Vice President said Alkermes staff would continue to play a key role in the development and manufacture of oral drugs. The two companies say they plan to enter into a subcontracting arrangement which could continue until the end of 2025. Alkermes also confirmed it would continue to retain all royalty revenues associated with products currently manufactured at the facility.
Advertisement
